Neimeth Nigeria's 271% stock surge masks lingering debt challenges
Neimeth Nigeria Plc, a pharmaceutical firm recovering from financial struggles, has seen its share price surge by 271% over the past year. The company's turnaround follows three straight years of losses, with a profit of N976.4 million reported in 2025. Despite this growth, its shares now trade at around 44 times earnings.
The company's financial rebound comes after years of setbacks. In 2025, Neimeth posted a profit after tax of N976.4 million, reversing a trend of losses. This improvement has driven investor confidence, pushing the share price to N10.45.
Neimeth's balance sheet remains under pressure. External debt stands at about N8.6 billion, far exceeding its share capital of N2.6 billion. To address this, the firm plans to restructure its share premium, using a scheme of arrangement to offset N1.8 billion in accumulated losses against a N2.3 billion share premium. The board, made up of 12 directors with a strong non-executive presence, oversees a company valued at roughly N14 billion. Majority shareholder Clinoscope recently cut its stake by half, reducing its holding to 12.9%. Meanwhile, Neimeth aims to raise N20 billion through a mix of equity instruments, including public offers, rights issues, or private placements.
Neimeth's recovery is marked by a sharp rise in share value and a return to profit. However, high debt levels and a need for fresh capital remain key challenges. The company's planned restructuring and fundraising efforts will determine its next steps in stabilising finances.
